These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34901562)

  • 1. Regulatory perspectives of combination products.
    Tian J; Song X; Wang Y; Cheng M; Lu S; Xu W; Gao G; Sun L; Tang Z; Wang M; Zhang X
    Bioact Mater; 2022 Apr; 10():492-503. PubMed ID: 34901562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory science for hernia mesh: Current status and future perspectives.
    Liu W; Xie Y; Zheng Y; He W; Qiao K; Meng H
    Bioact Mater; 2021 Feb; 6(2):420-432. PubMed ID: 32995670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A regulatory perspective on recombinant collagen-based medical devices.
    Liu W; Lin H; Zhao P; Xing L; Li J; Wang Z; Ju S; Shi X; Liu Y; Deng G; Gao G; Sun L; Zhang X
    Bioact Mater; 2022 Jun; 12():198-202. PubMed ID: 35310384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities.
    Shi J; Chen X; Hu H; Ung COL
    Front Public Health; 2023; 11():1172557. PubMed ID: 37213606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing medical device regulatory reforms for innovation, translation and industry development in China.
    Song X; Hu M; Li B; Zhang K; Zhang X; Wang L
    J Orthop Translat; 2022 Nov; 37():89-93. PubMed ID: 36262965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Visualization Models of Designation Pathway and Group Categorization of Device-Drug and Device-Biologic Combination Products Classification in the United States: Analysis of FDA Capsular Decisions.
    Uemura N; Kasanuki H; Umezu M
    Ther Innov Regul Sci; 2021 Jul; 55(4):807-817. PubMed ID: 33844189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of breakthrough devices designation in the United States and innovative medical devices designation in Korea for digital health software.
    Woo JH; Kim EC; Kim SM
    Expert Rev Med Devices; 2022 Mar; 19(3):213-228. PubMed ID: 35255755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Visualization Models of Designation Pathway and Group Categorization of Cell-Device and Protein-Device Combination Products in the United States.
    Uemura N; Kasanuki H; Umezu M
    Ther Innov Regul Sci; 2021 Nov; 55(6):1199-1213. PubMed ID: 34152563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.
    Rouse R; Kruhlak N; Weaver J; Burkhart K; Patel V; Strauss DG
    Ther Innov Regul Sci; 2018 Mar; 52(2):244-255. PubMed ID: 29568713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical Chemistry in the Regulatory Science of Medical Devices.
    Wang Y; Guan A; Wickramasekara S; Phillips KS
    Annu Rev Anal Chem (Palo Alto Calif); 2018 Jun; 11(1):307-327. PubMed ID: 29579404
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Jose J; S S; Mathew B; Parambi DGT
    Comb Chem High Throughput Screen; 2022; 25(12):1991-2000. PubMed ID: 34986768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulatory challenges of innovative customized combination products.
    Reis ME; Bettencourt A; Ribeiro HM
    Front Med (Lausanne); 2022; 9():821094. PubMed ID: 35935795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomedical applications of tissue engineering technology: regulatory issues.
    Hellman KB
    Tissue Eng; 1995; 1(2):203-10. PubMed ID: 19877928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of regulatory perspectives on innovative medical devices in Korea and the United States.
    Choe M; Shim JH; Heo CY
    Expert Rev Med Devices; 2022 Mar; 19(3):229-235. PubMed ID: 35293274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
    Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
    J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Care Network in the State of Qatar.
    Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
    Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-Based Quality and Compliance Management in Clinical Trials with Combination Products in Changing Global Regulatory Environment.
    Kaliaev AO; Malikova MA
    Ther Innov Regul Sci; 2020 Jul; 54(4):803-813. PubMed ID: 32557305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design control considerations for biologic-device combination products.
    Anderson D; Liu R; Anand Subramony J; Cammack J
    Adv Drug Deliv Rev; 2017 Mar; 112():101-105. PubMed ID: 28088344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.